SEPTIN9 and colorectal carcinoma: One of the latest DNA methylation-based biomarkers for CRC is the plasmatic septin 9 (SEPT9) promoter hypermethylation analyses, which has consistently demonstrated utility in detecting CRC in several clinical studies [13,14].